ReviewCell reports2025
Discovery of peptides as key regulators of metabolic and cardiovascular crosstalk.
Review in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Constrained diffusion-enabled construction of a highly expressed and robust peptide asparaginyl ligase.Chemical science · 2026Article
- LC-MS/MS Profiling of Blood Serum Reveals Disease-Enriched Peptides in Metabolic Syndrome.Journal of personalized medicine · 2026Article
- InversePep: Diffusion-driven structure-based inverse folding for functional peptides.Briefings in bioinformatics · 2026Article
- Emerging insights of bile acids in cardiovascular physiology and disease: from molecular mechanisms to therapeutic potential.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Peptides are fundamental regulators of metabolism, with several already developed as drugs, including glucagon-like peptide-1-based peptide therapeutics for diabetes and obesity. Despite their established importance, our understanding of their biosynthesis, modifications, receptor interactions, and signaling pathways remains incomplete. Advances in peptidomics and proteomics, particularly mass spectrometry, have facilitated peptide discovery and characterization, revealing novel roles for known peptides and uncovering previously unrecognized post-translational modifications. With the increasing prevalence of metabolic diseases driven by obesity, understanding the regulatory functions of peptide hormones has significant therapeutic potential. This review discusses the latest insights into peptide biology, highlighting key examples of peptides controlling tissue crosstalk, as well as how multi-omics technologies, computational approaches, and AI-driven methods are likely to expand our knowledge of peptide-mediated metabolic regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.